Skip to content

Comparison of analgesic effect between bupivacaine liposomes and ropivacaine on thoracic paravertebral nerve block in patients undergoing thoracoscopic surgery

Comparison of analgesic effect between bupivacaine liposomes and ropivacaine on thoracic paravertebral nerve block in patients undergoing thoracoscopic surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093464
Enrollment
Unknown
Registered
2024-12-05
Start date
2024-12-30
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung tumor

Interventions

Interventional group: thoracic paravertebral blockade with Lipome bupivacaine
Control group: thoracic paravertebral blockade with Ropivacaine

Sponsors

the First Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Patients aged 18-70 years, scheduled for elective Video-assisted thoracoscopic surgery for lung cancer . 2) Preoperative blood routine, biochemical, and electrocardiogram examinations have been completed without obvious abnormal. 3) Patients have no history of drug allergy, and respiratory, circulatory, liver, renal or endocrine disorders. 4) American Society of Anesthesiologists (ASA) classifications ?-?. 5) Body Mass Index(BMI)18 to 28 kg/m^2 6) Can accurately understand the NRS scoring criteria and the usage of PCIA 7) Signed the consents voluntarily

Exclusion criteria

Exclusion criteria: 1) Patients who are allergic to liposomal bupivacaine and any anesthesia related drugs; 2) Severe dysfunction of the heart, lungs, liver, and kidneys 3) History of chronic respiratory diseases (such as chronic obstructive pulmonary disease ,Emphysema or asthma), respiratory and pulmonary infections within 2 weeks before surgery; 4) Patients transitioning to open chest surgery during surgery; 5) Patients with other acute and chronic pain disorders; 6) Suffering from neurological and psychiatric disorders such as epilepsy and cognitive dysfunction; 7) patients and their family members refused to participate in this study

Design outcomes

Primary

MeasureTime frame
Numerical Rating Scale pain scores at rest and on movement;Consumption of hydromorphone recorded on patient-controlled analgesia(PCA) pump;Ratio of doses given and doses attempted; Frequency of rescue analgesia;

Secondary

MeasureTime frame
Incidence of adverse effects;The incidence and severity of pain after discharge o;

Countries

China

Contacts

Public ContactXiaoxia An

The First Affiliated Hospital, Zhejiang University School of Medicine

anxxls@163.com+86 138 5818 0512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026